相关临床试验
45
4 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
N/A
进行中（未招募）
3
6.7%
已完成
34
75.6%
尚未招募
1
2.2%
招募中
3
6.7%
终止
4
8.9%
暂无批准数据
- The FDA has issued an urgent alert after Abbott reported seven deaths and 736 serious injuries associated with defective FreeStyle Libre 3 and FreeStyle Libre 3 Plus glucose monitoring sensors that provide incorrect low glucose readings. - The affected sensors may lead to dangerous treatment decisions including excessive carbohydrate intake or delayed insulin doses, posing serious health risks to diabetes patients. - Abbott has initiated a recall of specific sensor models and is providing free replacements to affected customers through their verification website. - Healthcare providers are being instructed to inform patients about the issue and recommend immediate discontinuation of affected sensors.
- The Federal Circuit upheld the Patent Trial and Appeal Board's decision to cancel six claims from DexCom's US Patent No. 10,702,193 covering implantable glucose monitoring sensors. - The patent dispute originated from DexCom's June 2021 lawsuit against Abbott Diabetes Care for infringement of five patents, which settled after three years. - Abbott's validity challenge to the patent continued despite the settlement, with the USPTO defending the PTAB's obviousness determination that led to the patent claims cancellation.
- A 73-year-old breast cancer patient experienced severe hyperglycemia exceeding 500 mg/dL on day 11 of capivasertib treatment, despite having normal baseline glucose levels and no diabetes history. - Continuous glucose monitoring revealed that hyperglycemia occurred exclusively during capivasertib dosing days, with glucose levels rising 1-2 hours after drug intake and returning to baseline after 12 hours. - The Japan Diabetes Society and Japan Breast Cancer Society issued a safety warning on April 15, 2025, following a fatal case of diabetic ketoacidosis during early capivasertib treatment. - The case highlights the need for enhanced glucose monitoring strategies during capivasertib therapy, as routine laboratory assessments may miss transient hyperglycemic episodes that occur only on dosing days.
- Adults with type 2 diabetes achieved significant HbA1c reduction from 8.18% to 7% over 26 weeks using once-weekly insulin icodec combined with continuous glucose monitoring in the ONWARDS 9 trial. - Time in range improved dramatically by more than 20 percentage points, equivalent to an additional 5 hours and 11 minutes of optimal glucose control per day. - The combination therapy showed excellent safety profile with no severe hypoglycemic events and only 13 clinically significant episodes among 51 participants. - Researchers suggest this approach could advance precision diabetes management and potentially complement GLP-1 therapies for patients struggling to achieve target HbA1c levels.
